CN104245924B - 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途 - Google Patents

用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途 Download PDF

Info

Publication number
CN104245924B
CN104245924B CN201380021092.5A CN201380021092A CN104245924B CN 104245924 B CN104245924 B CN 104245924B CN 201380021092 A CN201380021092 A CN 201380021092A CN 104245924 B CN104245924 B CN 104245924B
Authority
CN
China
Prior art keywords
cells
cell
another embodiment
fasl
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380021092.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104245924A (zh
Inventor
S·亚科尼
N·阿斯肯纳西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellect Biotherapeutics Ltd
Quoin Pharmaceuticals Ltd
Original Assignee
Cellect Biotechnology Ltd
Cellect Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellect Biotechnology Ltd, Cellect Biotherapeutics Ltd filed Critical Cellect Biotechnology Ltd
Priority to CN201810972287.2A priority Critical patent/CN109116033A/zh
Publication of CN104245924A publication Critical patent/CN104245924A/zh
Application granted granted Critical
Publication of CN104245924B publication Critical patent/CN104245924B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
CN201380021092.5A 2012-03-06 2013-03-05 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途 Expired - Fee Related CN104245924B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810972287.2A CN109116033A (zh) 2012-03-06 2013-03-05 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607033P 2012-03-06 2012-03-06
US61/607,033 2012-03-06
PCT/IL2013/000026 WO2013132477A1 (en) 2012-03-06 2013-03-05 Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810972287.2A Division CN109116033A (zh) 2012-03-06 2013-03-05 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途

Publications (2)

Publication Number Publication Date
CN104245924A CN104245924A (zh) 2014-12-24
CN104245924B true CN104245924B (zh) 2020-05-01

Family

ID=49116028

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380021092.5A Expired - Fee Related CN104245924B (zh) 2012-03-06 2013-03-05 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途
CN201810972287.2A Pending CN109116033A (zh) 2012-03-06 2013-03-05 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810972287.2A Pending CN109116033A (zh) 2012-03-06 2013-03-05 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途

Country Status (11)

Country Link
US (2) US9783778B2 (enExample)
EP (2) EP2823040B1 (enExample)
JP (1) JP6429191B2 (enExample)
KR (1) KR101912982B1 (enExample)
CN (2) CN104245924B (enExample)
AU (1) AU2013229008B2 (enExample)
CA (1) CA2866358C (enExample)
DK (1) DK2823040T3 (enExample)
IL (1) IL234459B (enExample)
RU (1) RU2630301C2 (enExample)
WO (1) WO2013132477A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016116732A (ru) * 2013-10-09 2017-11-15 Сэллект Байотерапьютикс Лтд. Активация гемопоэтических клеток-предшественников путем предтрансплантационного воздействия лигандами рецепторов смерти
WO2016193986A2 (en) 2015-06-05 2016-12-08 Cellect Biotherapeutics Ltd. Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof
JP2021534747A (ja) * 2018-08-22 2021-12-16 セレクト バイオセラピューティクス リミテッド アポトーシス感受性細胞のモジュレーション
US20220002363A1 (en) * 2020-07-03 2022-01-06 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating pulmonary disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101517070A (zh) * 2006-05-31 2009-08-26 Styx有限责任公司 选择干细胞的方法及其用途
CN102123746A (zh) * 2008-06-13 2011-07-13 史密夫和内修有限公司 用于组织修复的固定装置

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS61235752A (ja) 1985-04-11 1986-10-21 Asahi Optical Co Ltd 細胞分離材、分離器および分離方法
IT8523298V0 (it) * 1985-10-02 1985-10-02 Pierrel Hospital Spa Catetere venoso centrale.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4979959A (en) 1986-10-17 1990-12-25 Bio-Metric Systems, Inc. Biocompatible coating for solid surfaces
US4885234A (en) 1988-09-29 1989-12-05 Eastman Kodak Company Photographic materials containing stable cyan coupler formulations
US5998024A (en) 1995-02-02 1999-12-07 Rainer H. Frey Biocompatible material and method of manufacture and use thereof
EA002819B1 (ru) 1997-05-14 2002-10-31 Авентис Фармасьютикалз Продактс Инк. Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция
US6040182A (en) 1997-11-12 2000-03-21 Becton Dickinson And Company Method and materials for efficiency protein immobilization on tissue culture treated assay plates
GB9724270D0 (en) 1997-11-17 1998-01-14 Babraham The Inst Methods and means for mutagenesis of dna
EP1076635B1 (en) 1998-04-22 2002-03-06 St. Jude Medical AB Biocompatible material for implants
US20010049115A1 (en) * 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
US20090130718A1 (en) 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
WO2003002761A1 (en) 2001-06-29 2003-01-09 Novozymes A/S Method of multimerization and site-directed mutagenesis
US20030044389A1 (en) 2001-07-02 2003-03-06 Brown Patrick O. Microarrays for cell phenotyping and manipulation
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
ATE519115T1 (de) * 2002-06-13 2011-08-15 Merck Patent Gmbh Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
US20060009623A1 (en) 2004-07-06 2006-01-12 National University Of Singapore C-terminal attachment of ligands to proteins for immobilization onto a support
US20080241109A1 (en) * 2004-10-01 2008-10-02 Marc Dupuis Method for Ex-Vivo Purging in Autologous Transplantation
US8252587B2 (en) * 2004-10-25 2012-08-28 Celerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
DE602005008265D1 (de) * 2005-12-23 2008-08-28 Biedermann Motech Gmbh Flexible Stabilisierungsvorrichtung zur dynamischen Stabilisierung von Knochen oder Wirbeln
CA2653881C (en) * 2006-05-31 2016-08-23 Styx Llc Methods of selecting stem cells and uses thereof
AU2008229636B2 (en) * 2007-03-16 2014-08-14 Qiagen Sciences Llc A cell-mediated immune response assay and kits therefor
KR100920729B1 (ko) 2007-10-01 2009-10-07 한국생명공학연구원 펩타이드 혼성체를 사용한 배향성이 조절된 항체단분자막의 제조방법
WO2009154840A2 (en) 2008-03-27 2009-12-23 Neostem, Inc. Compositions and methods using stem cells in cutaneous wound healing
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
WO2010051032A1 (en) * 2008-10-31 2010-05-06 Synthes Usa, Llc Method and device for activating stem cells
GB0823553D0 (en) 2008-12-24 2009-01-28 Immunosolv Ltd Cell separation technique
JP5327457B2 (ja) * 2009-03-27 2013-10-30 セイコーエプソン株式会社 がん細胞分離装置およびその製造方法
JP2010227313A (ja) * 2009-03-27 2010-10-14 Seiko Epson Corp がん細胞除去システムおよびがん細胞除去装置
EP2595637B1 (en) * 2010-07-22 2017-11-01 Cellect Biotherapeutics Ltd. Regulatory immune cells with enhanced targeted cell death effect

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101517070A (zh) * 2006-05-31 2009-08-26 Styx有限责任公司 选择干细胞的方法及其用途
CN102123746A (zh) * 2008-06-13 2011-07-13 史密夫和内修有限公司 用于组织修复的固定装置

Also Published As

Publication number Publication date
CN109116033A (zh) 2019-01-01
JP2015510758A (ja) 2015-04-13
JP6429191B2 (ja) 2018-11-28
CA2866358C (en) 2020-06-23
RU2630301C2 (ru) 2017-09-06
EP3486315A1 (en) 2019-05-22
EP2823040B1 (en) 2018-08-01
KR20150011796A (ko) 2015-02-02
WO2013132477A1 (en) 2013-09-12
US20150044182A1 (en) 2015-02-12
US20180208888A1 (en) 2018-07-26
CN104245924A (zh) 2014-12-24
KR101912982B1 (ko) 2018-10-29
AU2013229008B2 (en) 2018-11-08
RU2014138001A (ru) 2016-04-20
AU2013229008A1 (en) 2014-09-18
CA2866358A1 (en) 2013-09-12
US9783778B2 (en) 2017-10-10
EP2823040A1 (en) 2015-01-14
EP2823040A4 (en) 2016-01-06
DK2823040T3 (en) 2018-11-19
IL234459B (en) 2020-02-27

Similar Documents

Publication Publication Date Title
US20230331855A1 (en) Chimeric receptors and methods of use thereof
CN101835792B (zh) Foxm1肽和包含foxm1肽的药剂
Socié et al. Acute graft-versus-host disease: from the bench to the bedside
Boieri et al. The role of animal models in the study of hematopoietic stem cell transplantation and GvHD: a historical overview
JP5977238B2 (ja) 抗白血病／リンパ腫処置のための抗第三者セントラルメモリーｔ細胞の使用
TW200916114A (en) Cdca1 peptide and pharmaceutical agent comprising the same
WO2007082177A2 (en) Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity
US20180208888A1 (en) Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof
JP2006511208A (ja) 自己免疫疾患の治療の方法
EP3303563B1 (en) Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof
KR20050047500A (ko) 중간엽기질세포를 이용한 생착증진 방법
Shlomchik et al. The immunobiology of T cell therapies for leukemias
KR20060040671A (ko) 단구성 기원의 자기 유래 자가 관용성 유도 세포 및약제학적 제제에 있어서의 이의 용도
Ho et al. Donor lymphocyte infusions
Jones The immunobiology of graft-versus-host disease across a minor histocompatibility antigen barrier
Albanese et al. Prenatal cellular transplantation
Ditschkowski et al. Favourable outcome of allogeneic haematopoietic stem cell transplantation (HSCT) for patients with myelofibrosis in non-advanced disease stages
EA051270B1 (ru) Химерные рецепторы и способы их применения
EA040586B1 (ru) Химерные рецепторы и способы их применения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Israel Kfar Saba

Applicant after: CELLECT BIOTHERAPEUTICS LTD.

Address before: Israel Kfar Saba

Applicant before: CELLECT BIOTECHNOLOGY LTD.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200501

CF01 Termination of patent right due to non-payment of annual fee